 This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor EGFR and anaplastic lymphoma kinase ALK wild-type and with PD-L1-high expression 